Sun Yat-sen University

This trial tests a new drug called Cadonilimab in 28 people with advanced colorectal cancer that has not responded to standard immunotherapy. The drug is a bispecific antibody that targets two immune checkpoints (PD-1 and CTLA-4) to potentially reactivate the immune system agains…

This study tests a daily oral drug called surufatinib in 47 people with advanced osteosarcoma or soft tissue sarcoma that has not responded to standard chemotherapy. The goal is to see if the drug can slow tumor growth and improve survival. Participants take the drug in 21-day cy…

This study tests whether giving a combination of three drugs (finotonlimab, cetuximab, and docetaxel) before surgery can shrink tumors in people whose head and neck cancer has come back after prior immunotherapy and chemotherapy. The goal is to see if this approach leads to fewer…

This phase 3 trial is testing whether adding the immunotherapy drug tislelizumab to standard chemotherapy can improve outcomes for people with locoregionally advanced nasopharyngeal carcinoma. About 450 participants will receive either tislelizumab plus chemo or a placebo plus ch…

This study tests whether eye pressure-lowering medication can slow the progression of severe nearsightedness (high myopia) in adults. Researchers will measure changes in eye length and vision over time. The trial includes 152 participants aged 18 to 65 with worsening high myopia …

This study looks at whether giving chemotherapy both before and after surgery (perioperative) is better than only after surgery for people with advanced colon cancer. About 738 participants will be randomly assigned to one of two groups. The goal is to see if the perioperative ap…

This study tests whether the antiviral drug entecavir can prevent hepatitis B from reactivating in people with a type of blood cancer (CD20-positive B-cell lymphoma) who have had hepatitis B in the past but cleared it. The 84 participants will take entecavir before starting their…

This study tests a treatment called photodynamic therapy (PDT) for people whose superficial esophageal cancer has come back or remained after standard treatments. Patients receive an injection of hematoporphyrin, a drug that makes cancer cells sensitive to light, then a laser is …

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can completely eliminate tumors in people with localized triple-negative breast cancer. About 51 women with early-stage, untreated disease will receive the combination, then…

This phase II trial is testing whether combining an immunotherapy drug (PD-1 antibody) with standard chemotherapy and radiation can help people whose nasopharyngeal cancer has come back after initial treatment. The study includes 68 participants with high-risk recurrent cancer th…

This study tests whether giving radiation to a smaller area of the neck is as good as the standard larger area for treating nasopharyngeal cancer that hasn't spread. About 474 adults with newly diagnosed cancer will be randomly assigned to one of two radiation plans. The goal is …

This phase II trial is testing whether combining targeted radiation (SBRT) with an immunotherapy drug (camrelizumab) and standard chemotherapy can help control nasopharyngeal cancer that has spread to a few other parts of the body. The study involves 41 participants who have not …

This phase 2 trial tests whether adding the immunotherapy drug sintilimab to the chemotherapy drug capecitabine can better prevent nasopharyngeal cancer from returning after initial treatment. About 150 patients whose cancer did not fully respond to induction chemotherapy will re…

This phase 2 trial is testing whether combining two drugs, ensartinib and bevacizumab, can help people with advanced lung cancer that has both an ALK rearrangement and a TP53 mutation. The study includes 47 participants who take ensartinib daily and receive bevacizumab every thre…

This study tests a new combination treatment for adults with liver cancer that no longer responds to standard targeted-immunotherapy. About 62 participants will receive QL1706 (a dual immune drug) along with either local chemotherapy or another targeted drug. The goal is to see i…

This study tests a new drug called cadonilimab, combined with chemotherapy and radiation, for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if this combination can better control the cancer and prevent it from coming back. About 46 p…

This study tests a three-step treatment for elderly patients (ages 60-80) with a high-risk type of lymphoma called double-expressor DLBCL. First, patients receive a chemotherapy-free drug combination. Depending on how well the cancer responds, they then get standard chemotherapy …

This study tests whether combining two drugs—serplulimab and fruquintinib—can prevent kidney cancer from returning after surgery in people with a rare, aggressive type called non-clear cell renal cell carcinoma. About 40 adults at high risk of recurrence will receive both drugs f…

This study tests a new medicine called AK112 (Yivoximab) for people with advanced kidney cancer that has spread. The drug works in two ways: it helps the immune system attack cancer cells and blocks blood vessels that feed tumors. About 60 participants will receive the drug every…

This study tests a combination of two drugs, cadonilimab and lenvatinib, in 32 people with advanced endometrial cancer that has spread or come back and no longer responds to standard chemotherapy. The goal is to see if the combination shrinks tumors and how long it keeps the canc…

This phase 2 trial tests a combination of two drugs—zimberelimab (an immunotherapy) and lenvatinib (a targeted therapy)—in 30 patients with advanced cervical cancer that has worsened after prior immunotherapy. The goal is to see if the combo can shrink tumors or slow disease prog…

This study tests a new treatment for people with a rare and aggressive type of lymphoma (NK/T-cell lymphoma) that has spread. The treatment combines an immunotherapy drug (sintilimab) with a chemotherapy regimen (P-GemOx). The goal is to see if this combination is safe and effect…

This study looks at whether closing the pelvic floor with stitches after removing rectal cancer can stop the bowel from getting blocked. About 516 people having keyhole surgery for mid-low rectal cancer will be randomly assigned to get the closure or not. The main goal is to see …

This study tests a combination of two drugs (toripalimab and bevacizumab) alongside three types of artery-directed treatments for people with liver cancer that cannot be removed by surgery. The goal is to see which artery treatment works best with the drug combo to control the ca…

This phase 2 trial tests whether combining two immune-boosting drugs (ipromlimab and tuvonralimab) with standard chemotherapy before surgery can help shrink tumors in people with locally advanced esophageal cancer. The study involves 62 participants and is currently active but no…

This phase II trial is testing a combination of three drugs—anlotinib, penpulimab, and capecitabine—as a first treatment for people whose nasopharyngeal cancer has come back or spread. The study includes 59 adults aged 18 to 65 who have not had prior systemic therapy for their re…

This study tests whether adding a liver-directed chemotherapy infusion to a two-drug immunotherapy regimen can help people with advanced liver cancer that has spread to the main vein of the liver. About 214 participants will be randomly assigned to receive either the triple thera…

This study tests whether adding the drug anlotinib hydrochloride to the standard Stupp regimen (chemoradiation) can help people with newly diagnosed glioblastoma live longer without their cancer growing. About 150 adults aged 18-75 with this aggressive brain tumor are participati…

This phase 2 trial is testing whether a combination of chemotherapy, an immunotherapy drug called toripalimab, and radiation can effectively treat muscle-invasive bladder cancer while allowing patients to keep their bladder. About 71 adults with this type of bladder cancer will r…

This study tests whether adding thymosin alpha 1 to standard chemoradiation and immunotherapy helps patients with advanced non-small cell lung cancer complete a full year of immunotherapy. About 114 adults will participate. The goal is to see if this approach improves survival an…

This phase 2 trial tests whether adding the drug apatinib to standard chemotherapy and radiation helps people with advanced esophageal cancer that cannot be removed by surgery. About 170 participants will receive either the standard treatment or the standard treatment plus apatin…

This phase 2 trial is testing a combination of three drugs—surufatinib, sintilimab, and a standard chemotherapy (nab-paclitaxel plus gemcitabine)—as a first treatment for people with advanced or metastatic pancreatic cancer. The study enrolled 32 participants and aims to see how …

This phase 3 trial tests whether using smaller radiation targets after initial chemotherapy can control advanced nasopharyngeal cancer just as well as standard larger targets, while reducing side effects. About 445 patients with stage III-IVa disease are enrolled. The study compa…

This study tests whether wearing pressurized gloves and foot caps during chemotherapy can prevent nerve damage (peripheral neuropathy) caused by the drug paclitaxel. It involves 182 people with nasopharyngeal cancer who have not yet started treatment. Each patient serves as their…

This study looks at whether giving morphine into the spine (intrathecal) before laparoscopic colon cancer surgery helps patients feel better and recover faster. About 252 adults having this surgery will be invited to join. The goal is to see if this approach reduces pain, cuts do…

This study looks at how the bacteria in the gut (microbiome) are connected to cancer-related symptoms in children aged 5-18 with acute lymphoblastic leukemia. Researchers will collect stool samples and symptom reports at several points during chemotherapy. The goal is to understa…

This study looks at how the heart works during a 6-minute walk test in people with advanced lung cancer who are getting chemotherapy, radiation, and immunotherapy. The goal is to see if heart measurements can help predict side effects and how well patients do over time. About 231…

This study tests a new way to grade carotid plaques using ultrasound, called Plaque-RADS, to see if it can predict stroke risk better than current methods. Researchers will collect data from 855 people with asymptomatic carotid plaques, both from past records and new patients. Th…